Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and “Reopening”

Daniel K. Jin, Daniel. J. Nesbitt, Jenny Yang, Haidee Chen, View ORCID ProfileJulie Horowitz, Marcus Jones, Rianna Vandergaast, Timothy Carey, Samantha Reiter, Stephen J Russell, View ORCID ProfileChristos Kyratsous, Andrea Hooper, Jennifer Hamilton, Manuel Ferreira, Sarah Deng, Donna Straus, View ORCID ProfileAris Baras, Christopher D. Hillyer, View ORCID ProfileLarry L. Luchsinger
doi: https://doi.org/10.1101/2020.11.06.20220087
Daniel K. Jin
1Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel. J. Nesbitt
1Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny Yang
1Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haidee Chen
1Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Horowitz
3Regeneron Genetics Center, Tarrytown, NY 10591, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Julie Horowitz
Marcus Jones
3Regeneron Genetics Center, Tarrytown, NY 10591, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rianna Vandergaast
4Imanis Life Sciences, Rochester, MN 55901
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Carey
4Imanis Life Sciences, Rochester, MN 55901
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Reiter
4Imanis Life Sciences, Rochester, MN 55901
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen J Russell
5Vyriad, Inc., Rochester, MN 55901
4Imanis Life Sciences, Rochester, MN 55901
7Mayo Clinic Department of Molecular Medicine, Rochester, MN 55905
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos Kyratsous
8Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christos Kyratsous
Andrea Hooper
8Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Hamilton
8Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Ferreira
3Regeneron Genetics Center, Tarrytown, NY 10591, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Deng
8Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna Straus
2New York Blood Center Enterprises, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aris Baras
3Regeneron Genetics Center, Tarrytown, NY 10591, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aris Baras
Christopher D. Hillyer
1Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
2New York Blood Center Enterprises, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larry L. Luchsinger
1Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Larry L. Luchsinger
  • For correspondence: lluchsinger{at}nybc.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic and local, regional and national public health policies designed to limit the spread of the epidemic as well as “reopen” cities and states, are best informed by serum neutralizing antibody titers measured by reproducible, high throughput, and statically credible antibody (Ab) assays. To date, a myriad of Ab tests, both available and authorized for emergency use by the FDA, has led to confusion rather than insight per se. The present study reports the results of a rapid, point-in-time 1,000-person cohort study using serial blood donors in the New York City metropolitan area (NYC) using multiple serological tests, including enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). These were then tested and associated with assays for neutralizing Ab (NAb). Of the 1,000 NYC blood donor samples in late June and early July 2020, 12.1% and 10.9% were seropositive using the Ortho Total Ig and the Abbott IgG HTSA assays, respectively. These serological assays correlated with neutralization activity specific to SARS-CoV-2. The data reported herein suggest that seroconversion in this population occurred in approximately 1 in 8 blood donors from the beginning of the pandemic in NYC (considered March 1, 2020). These findings deviate with an earlier seroprevalence study in NYC showing 13.7% positivity. Collectively however, these data demonstrate that a low number of individuals have serologic evidence of infection during this “first wave” and suggest that the notion of “herd immunity” at rates of ∼60% or higher are not near. Furthermore, the data presented herein show that the nature of the Ab-based immunity is not invariably associated with the development of NAb. While the blood donor population may not mimic precisely the NYC population as a whole, rapid assessment of seroprevalence in this cohort and serial reassessment could aid public health decision making.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding for this project was provided by the New York Blood Center, the Rockefeller University and Regeneron Pharmaceuticals, Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approval for donation and collection of blood from donors was attained by written consent. All donors were over 16 years of age. Ethical oversight of seroprevalence donation protocols was obtained from the institutional review board of the New York Blood Center.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All raw data will be made available upon request to the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 07, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and “Reopening”
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and “Reopening”
Daniel K. Jin, Daniel. J. Nesbitt, Jenny Yang, Haidee Chen, Julie Horowitz, Marcus Jones, Rianna Vandergaast, Timothy Carey, Samantha Reiter, Stephen J Russell, Christos Kyratsous, Andrea Hooper, Jennifer Hamilton, Manuel Ferreira, Sarah Deng, Donna Straus, Aris Baras, Christopher D. Hillyer, Larry L. Luchsinger
medRxiv 2020.11.06.20220087; doi: https://doi.org/10.1101/2020.11.06.20220087
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and “Reopening”
Daniel K. Jin, Daniel. J. Nesbitt, Jenny Yang, Haidee Chen, Julie Horowitz, Marcus Jones, Rianna Vandergaast, Timothy Carey, Samantha Reiter, Stephen J Russell, Christos Kyratsous, Andrea Hooper, Jennifer Hamilton, Manuel Ferreira, Sarah Deng, Donna Straus, Aris Baras, Christopher D. Hillyer, Larry L. Luchsinger
medRxiv 2020.11.06.20220087; doi: https://doi.org/10.1101/2020.11.06.20220087

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (754)
  • Anesthesia (221)
  • Cardiovascular Medicine (3287)
  • Dentistry and Oral Medicine (363)
  • Dermatology (277)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1169)
  • Epidemiology (13355)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5144)
  • Geriatric Medicine (481)
  • Health Economics (782)
  • Health Informatics (3263)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (429)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14619)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4916)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (882)
  • Occupational and Environmental Health (795)
  • Oncology (2518)
  • Ophthalmology (723)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (556)
  • Psychiatry and Clinical Psychology (4202)
  • Public and Global Health (7494)
  • Radiology and Imaging (1704)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (205)